IL178242A0 - Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase - Google Patents

Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase

Info

Publication number
IL178242A0
IL178242A0 IL178242A IL17824206A IL178242A0 IL 178242 A0 IL178242 A0 IL 178242A0 IL 178242 A IL178242 A IL 178242A IL 17824206 A IL17824206 A IL 17824206A IL 178242 A0 IL178242 A0 IL 178242A0
Authority
IL
Israel
Prior art keywords
neuroprotection
protein kinase
novel method
activated protein
pharmacological inhibition
Prior art date
Application number
IL178242A
Other languages
English (en)
Original Assignee
Univ Johns Hopkins
Fasgen Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Johns Hopkins, Fasgen Llc filed Critical Univ Johns Hopkins
Publication of IL178242A0 publication Critical patent/IL178242A0/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/365—Lactones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/70—Carbohydrates; Sugars; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Epidemiology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Vascular Medicine (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Urology & Nephrology (AREA)
  • Cardiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL178242A 2004-03-24 2006-09-21 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase IL178242A0 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US55600004P 2004-03-24 2004-03-24
PCT/US2005/009797 WO2005092068A2 (en) 2004-03-24 2005-03-23 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase

Publications (1)

Publication Number Publication Date
IL178242A0 true IL178242A0 (en) 2007-03-08

Family

ID=35056772

Family Applications (1)

Application Number Title Priority Date Filing Date
IL178242A IL178242A0 (en) 2004-03-24 2006-09-21 Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase

Country Status (11)

Country Link
US (1) US8293791B2 (https=)
EP (1) EP1734973A4 (https=)
JP (1) JP2008504228A (https=)
KR (2) KR20070085093A (https=)
CN (1) CN101132802A (https=)
AU (1) AU2005226731A1 (https=)
BR (1) BRPI0509085A (https=)
CA (1) CA2560843A1 (https=)
IL (1) IL178242A0 (https=)
MX (1) MXPA06010916A (https=)
WO (1) WO2005092068A2 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MXPA06010916A (es) 2004-03-24 2007-07-25 Fasgen Llc Novedoso metodo de proteccion neurologica mediante inhibicion farmacologica de proteina quinasa activada por amp.
KR101152607B1 (ko) 2005-12-20 2012-06-05 에스케이케미칼주식회사 ６-[４-(２-피페리딘-1-일-에톡시)-페닐]-３-피리딘-４-일-피라졸로[１,５-ａ]피리미딘의 제조방법
KR101787116B1 (ko) 2009-01-28 2017-10-18 케러 테라퓨틱스, 인코포레이티드 바이시클릭 피라졸로-헤테로사이클
US7741350B1 (en) * 2009-01-28 2010-06-22 Cara Therapeutics, Inc. Bicyclic pyrazolo-heterocycles
EP2978307B1 (en) 2013-03-28 2018-12-26 The Trustees of Columbia University in the City of New York Reperfusion with omega-3 glycerides promotes donor organ protection for transplantation
KR101532211B1 (ko) * 2014-04-30 2015-06-30 세종대학교산학협력단 Ampk 억제기능에 기반한 뇌졸중 치료용 약학적 조성물 및 방법
CN119868551B (zh) * 2024-11-28 2026-04-14 四川大学华西医院 F-box蛋白48的抑制剂的新用途和治疗缺血性脑血管病的药物

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB9602080D0 (en) * 1996-02-02 1996-04-03 Pfizer Ltd Pharmaceutical compounds
US5981575A (en) * 1996-11-15 1999-11-09 Johns Hopkins University, The Inhibition of fatty acid synthase as a means to reduce adipocyte mass
CO5180581A1 (es) 1999-09-30 2002-07-30 Pfizer Prod Inc Compuestos para el tratamiento de la isquemia ciones farmaceuticas que los contienen para el tratamiento de la isquemia
IL147696A0 (en) * 2001-01-25 2002-08-14 Pfizer Prod Inc Combination therapy
US6423705B1 (en) * 2001-01-25 2002-07-23 Pfizer Inc. Combination therapy
MXPA06010916A (es) 2004-03-24 2007-07-25 Fasgen Llc Novedoso metodo de proteccion neurologica mediante inhibicion farmacologica de proteina quinasa activada por amp.

Also Published As

Publication number Publication date
KR20070085093A (ko) 2007-08-27
US20090137665A1 (en) 2009-05-28
MXPA06010916A (es) 2007-07-25
EP1734973A4 (en) 2010-08-04
JP2008504228A (ja) 2008-02-14
EP1734973A2 (en) 2006-12-27
AU2005226731A1 (en) 2005-10-06
WO2005092068A2 (en) 2005-10-06
KR101283416B1 (ko) 2013-07-08
BRPI0509085A (pt) 2007-08-21
US8293791B2 (en) 2012-10-23
CN101132802A (zh) 2008-02-27
KR20120078756A (ko) 2012-07-10
CA2560843A1 (en) 2005-10-06
WO2005092068A3 (en) 2007-09-20

Similar Documents

Publication Publication Date Title
IL190727A0 (en) Method of inhibiting flt3 kinase
GB0704028D0 (en) Method of expansion
IL181303A0 (en) Method for the production of dihydropteridinones
IL196051A0 (en) Cyclopenta [d] pyrimidines as akt protein kinase inhibitors
SI2402325T1 (sl) Hidroksilirani ciklopenta(d)pirimidini kot inhibitorji AKT protein kinaze
ZA200608444B (en) Barley for production of flavor-stable beverage
WO2008076946A9 (en) Methods of neuroprotection by cyclin-dependent kinase inhibition
IL182472A0 (en) Fermentative production of mannitol
IL181185A0 (en) Novel polymorphs of azabicyclohexane
IL178242A0 (en) Novel method of neuroprotection by pharmacological inhibition of amp-activated protein kinase
EP1804582A4 (en) POLYMORPH SHAPES OF TADALAFIL
IL182544A0 (en) Production method of pyrimidine compounds
ZA200703495B (en) Process for the preparation of irbesartan hydrochloride
IL181339A0 (en) Method for the production of diarylcycloalkyl derivatives
IL180345A0 (en) Improved process for the manufacture of mirtazapine
HU0401379D0 (en) Process for the preparation of risperidon
GB0511084D0 (en) An improved method of manufacturing tiles
PL384045A1 (pl) Sposób wytwarzania olanzapiny
GB2414238B (en) Method for the preparation of trilostane
IL178237A0 (en) Process for the preparation of rosiglitazone
HU0402163D0 (en) Process for the preparation of risperidone
HK1119568A (en) Method of inhibiting flt3 kinase
HU0401827D0 (en) Method for production of ceramics
PL372016A1 (pl) Sposób wytwarzania pochodnych N-fenylo-2-pirymidynoamin
PL369884A1 (pl) Sposób wytwarzania podstawionych cyjanowinylooksiranów